Background on Kimberly-Clark and Kenvue
Kimberly-Clark, a well-known American company that manufactures personal hygiene and care products, announced its plan to acquire Kenvue, another prominent U.S.-based consumer health company, in November 2025. The acquisition aims to combine their product portfolios, including well-known brands with annual sales exceeding $10 billion, reaching nearly half of the global population across various life stages.
Kenvue Acquisition Vote and Investor Support
Mike Hsu, the CEO of Kimberly-Clark, reported that a significant portion of investors had already voted on the Kenvue acquisition by Monday, with over 90% expressing their support. This strong endorsement reinforces confidence in the operation.
“We feel good about that,” Hsu stated during a conference with analysts after reporting fourth-quarter 2025 results. “I hope the voting reflects the very positive feedback we’ve heard from our investors,” he added.
Timeline and Regulatory Approvals
The CEO mentioned that the deal is expected to close in the second half of the year, pending regulatory approvals. He expressed optimism about the regulatory process, stating it is on track and aligns with their initial expectations.
“I believe the regulatory process is going well and is consistent with our initial expectations,” Hsu said, referring to the antitrust filing in the U.S., which Kimberly-Clark and Kenvue submitted shortly after announcing the transaction. They plan to complete filings in all applicable international jurisdictions by early February.
Investment Plans for Kenvue
Hsu emphasized that Kimberly-Clark intends to make “very good” investments in Kenvue’s brands, portfolio, and production capabilities. This acquisition is a crucial step in their ongoing transformation, enhancing long-term growth potential for both companies.
“We have the right foundation and a proven playbook to capitalize on our pending acquisition… It’s the next step in our transformation that will boost our momentum. Our focus is ensuring both companies have substantial long-term earnings potential,” Hsu explained.
Key Brands and Market Reach
Kenvue owns popular consumer health brands such as Listerine, Neutrogena, and Tylenol. By merging with Kimberly-Clark, the combined entity will offer a broader range of products to nearly half of the world’s population across different life stages. Some of Kimberly-Clark’s well-known brands include Huggies, Kleenex, Kotex, and Cottonelle.
Key Questions and Answers
- What is the acquisition about? Kimberly-Clark plans to acquire Kenvue, a consumer health company, for approximately $48.7 billion.
- Why is this acquisition significant? The merger combines two prominent American companies, integrating their product portfolios and reaching nearly half of the global population across various life stages.
- What brands are involved? Kenvue owns Listerine, Neutrogena, and Tylenol, while Kimberly-Clark is known for Huggies, Kleenex, Kotex, and Cottonelle.
- When is the acquisition expected to close? The deal is anticipated to close in the second half of the year, pending regulatory approvals.
- What investments will be made in Kenvue? Kimberly-Clark plans to invest in Kenvue’s brands, portfolio, and production capabilities to maximize the acquisition’s potential.
